Schizophrenia (SCZ) genomics has achieved unprecedented advances. A decade ago, there was perhaps one solid finding, and there are now 130+ loci that meet consensus criteria for significance and replication. The Swedish SCZ Study (S3) and its investigators were centrally important to these advances. Genetic analyses of S3 samples have been major parts of multiple high profile papers. We cooperate well with other groups, and are leaders in the PGC. There is more to do. Thus, this is a competitive renewal for the S3 project. The S3 is arguably the largest and best-characterized SCZ sample anywhere: we propose to make it larger and more informative. In each prior R01, we accomplished far more than we proposed. We now propose aims designed to maximize the informativeness of S3 by doubling its size, adding cognitive phenotypes, and innovative analyses. Critically, this work is multi-funded and maximizes contributions from others and minimizes NIH budgetary requests.
Specific Aims (1) Augment S3 dataset by doubling the sample size, add cognitive phenotypes, conduct comprehensive genomic characterization, impute to a Sweden-specific reference panel, and add new Swedish register linkages. Output: a large and comprehensive dataset ready for analysis. (2) Analysis: increase knowledge of the genetic basis of SCZ. Integrate data from Aim 1 with all other world samples to discover compellingly associated loci. Add multi-omic integration: combine, annotate, and rigorously evaluate results with all available epigenomic and gene expression data (e.g., CommonMind, psychENCODE). Output: SCZ associations across the allelic spectrum, specific hypotheses about the immediate biological impact of genetic variation implicated in SCZ. Successful completion of this work - capitalizing on cutting-edge technologies and a highly productive decade- long collaboration - is highly likely to advance knowledge of SCZ by identifying more loci, providing specific biological hypotheses, and understanding of GxE action and interaction. This study is preclinical. Although not proposed here due to complexity and expense, we will immediate prioritize any potential therapeutic target via collaborations (e.g., with Dr Sullivan's UNC colleague and antipsychotic expert Dr Bryan Roth). The work proposed is highly efficient / cost-effective due to our multi-funding model. We have minimized costs (while maximizing the science we can achieve) via multiple strategic partnerships. We use consultancies to bring well-funded investigators into S3. We routinely use multiple technologies to enhance collaboration.

Public Health Relevance

The Swedish SCZ Study (S3) is arguably the largest and best-characterized SCZ sample in the world: we propose to make it larger and more informative. In each prior R01, we accomplished far more than we proposed. We now propose aims designed to maximize the informativeness of S3 by doubling its size, adding cognitive phenotypes, and innovative analyses. This work is highly likely to increase knowledge of the genetic basis of SCZ and its clinical and population relevance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH077139-08
Application #
9117634
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Addington, Anjene M
Project Start
2006-04-01
Project End
2019-04-30
Budget Start
2016-05-07
Budget End
2017-04-30
Support Year
8
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Martin, Alicia R; Karczewski, Konrad J; Kerminen, Sini et al. (2018) Haplotype Sharing Provides Insights into Fine-Scale Population History and Disease in Finland. Am J Hum Genet 102:760-775
Ganna, Andrea; Satterstrom, F Kyle; Zekavat, Seyedeh M et al. (2018) Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet 102:1204-1211
Curtis, David; Coelewij, Leda; Liu, Shou-Hwa et al. (2018) Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology. Behav Genet 48:198-208
Magri, Chiara; Giacopuzzi, Edoardo; La Via, Luca et al. (2018) A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme. Sci Rep 8:15470
Rao, A R; Yourshaw, M; Christensen, B et al. (2017) Rare deleterious mutations are associated with disease in bipolar disorder families. Mol Psychiatry 22:1009-1014
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Leonenko, Ganna; Richards, Alexander L; Walters, James T et al. (2017) Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 174:724-731
Direk, Nese; Williams, Stephanie; Smith, Jennifer A et al. (2017) An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biol Psychiatry 82:322-329
Singh, Tarjinder; Kurki, Mitja I; Curtis, David et al. (2016) Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19:571-7
Curtis, David (2016) Pathway analysis of whole exome sequence data provides further support for the involvement of histone modification in the aetiology of schizophrenia. Psychiatr Genet 26:223-7

Showing the most recent 10 out of 78 publications